Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population

Immunologic Research

Volumn 56, Issue 2-3, 2013, Pages 439-443

  Szekanecz, Zoltán ^a   Szabó, Zoltán ^a   Zeher, Margit ^a   Soós, Lilla ^a   Dankó, Katalin ^a   Horváth, Ildikó ^a   Lakos, Gabriella ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

ACPA; Anti CCP; Citrullination; Rheumatoid arthritis

Indexed keywords

ANTI MUTATED CITRULLINATED VIMENTIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PERFORMANCE; POPULATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; HUMANS; PEPTIDES, CYCLIC; PROGNOSIS; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 84879552101     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8425-8     Document Type: Article

References (18)

1. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130-6. (Pubitemid 40488741)
2. Szodoray P, Szabo Z, Kapitany A, Gyetvai A, Lakos G, Szanto S, et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev. 2010;9(3):140-3.
3. Cooles FA, Isaacs JD. Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol. 2011;23(3):233-40.
4. Besenyei T, Gyetvai A, Szabo Z, Fekete A, Kapitany A, Szodoray P, et al. Associations of HLA-shared epitope, anti-citrullinated peptide antibodies and lifestyle-related factors in Hungarian patients with rheumatoid arthritis: data from the first Central-Eastern European cohort. Joint Bone Spine. 2011;78(6):652-3.
5. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43(1):155-63. (Pubitemid 30368225)
6. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-8.
7. Klareskog L, Padyukov L, Lorentzen J, Alfredsson L. Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006;2(8):425-33. (Pubitemid 44203826)
8. Klareskog L, Widhe M, Hermansson M, Ronnelid J. Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol. 2008;20(3):300-5. (Pubitemid 351483320)
9. Szekanecz Z, Soos L, Szabo Z, Fekete A, Kapitany A, Vegvari A, et al. Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets? Clin Rev Allergy Immunol. 2008;34(1):26-31.
10. van Venrooij WJ, Zendman AJ, Pruijn GJ. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev. 2006;6(1):37-41. (Pubitemid 44716772)
11. Lakos G, Soos L, Fekete A, Szabo Z, Zeher M, Horvath IF, et al. Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope. Clin Exp Rheumatol. 2008;26(2):253-60. (Pubitemid 351673956)
12. dos Anjos LM, Pereira IA, d'Orsi E, Seaman AP, Burlingame RW, Morato EF. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol. 2009;28(2):153-8.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24. (Pubitemid 18091653)
14. Szekanecz Z, Szabó Z, Soós L, Zeher M, Horváth IF, Dankó K, Sipka S, Lakos G. The Inova CCP3.1 IgA/IgG ELISA represents significant improvement in the laboratory diagnosis of rheumatoid arthritis. Arthritis Rheum. 2007;56(9 Suppl):S716.
15. Szekanecz ZTJ, Szabó Z, Soós L, Zeher M, Horváth IF, Dankó K, Sipka S, Lakos G. The Inova CCP3.1 IgA/IgG ELISA represents significant improvement in the laboratory diagnosis of rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):568.
16. Bartoloni E, Alunno A, Bistoni O, Bizzaro N, Migliorini P, Morozzi G, Doria A, Mathieu A, Lotzniker M, Allegri F, Riccieri V, Alpini C, Gabrielli A, Tampoia M, Gerli R. Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) investigators. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev. 2012;11:815-20.
17. Mutlu N, Bicakcigil M, Tasan DA, Kaya A, Yavuz S, Ozden AI. Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis. J Rheumatol. 2009;36:491-500.
18. Debaugnies F, Servais G, Badot V, Noubouossie D, Willems D, Corazza F. Anti-cyclic citrullinated peptide antibodies: a comparison of different assays for the diagnosis of rheumatoid arthritis. Scand J Rheumatol. 2012 Nov 6. (Epub ahead of print).